Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus
2007

Insulin Aspart vs Regular Human Insulin for Gestational Diabetes

Sample size: 27 publication Evidence: moderate

Author Information

Author(s): Pettitt D. J., Ospina P., Howard C., Zisser H., Jovanovic L.

Primary Institution: Sansum Diabetes Research Institute

Hypothesis

The use of a rapid-acting insulin analogue, insulin aspart (IAsp), may improve postprandial glycaemia during pregnancy complicated by gestational diabetes.

Conclusion

Insulin aspart was more effective than regular human insulin in decreasing postprandial glucose concentrations in women with gestational diabetes.

Supporting Evidence

  • Insulin aspart led to a greater reduction in postprandial glucose levels compared to regular insulin.
  • Both treatment groups maintained good overall glycaemic control during the study.
  • No major hypoglycaemic events were reported during the study.
  • Insulin aspart was administered 5 minutes before meals, while regular insulin was given 30 minutes prior.

Takeaway

This study found that a new type of insulin, insulin aspart, works better than regular insulin for pregnant women with diabetes, helping to keep their blood sugar levels lower after meals.

Methodology

A randomized, parallel-group, open-label trial comparing insulin aspart and regular human insulin in 27 women with gestational diabetes.

Potential Biases

Potential bias due to the open-label design.

Limitations

The study was limited to a small sample size and a single center.

Participant Demographics

Most participants were Latino, with an average age of 30.7 years.

Statistical Information

P-Value

0.003

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/j.1464-5491.2007.02247.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication